Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-boehringer-ingelheim-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance-6195